NKGN VS MRK Stock Comparison
Performance
NKGN10/100
10/100
NKGN returned -53.87% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.
MRK100/100
100/100
MRK returned 1.78% in the last 12 months. Based on SPY's performance of -13.80%, its performance is above average giving it a score of 100 of 100.
Volatility
NKGN10/100
10/100
NKGN has had a lower than average amount of volatility over the last 12 months giving it a score of 10 of 100.
MRK52/100
52/100
MRK has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
Analyst Price Targets
NKGN
"Analyst Price Targets" not found for NKGN
MRK68/100
68/100
21 analysts offer 12-month price targets for MRK. Together, they have an average target of 113.88, the most optimistic target put MRK at 294 within 12-months and the most pessimistic has MRK at 80.
Technicals
NKGN
"Technicals" not found for NKGN
MRK10/100
10/100
MRK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
Earnings
NKGN
"Earnings" not found for NKGN
MRK53/100
53/100
MRK has missed earnings 3 times in the last 20 quarters.
Profit
NKGN
"Profit" not found for NKGN
MRK66/100
66/100
Out of the last 20 quarters, MRK has had 17 profitable quarters and has increased their profits year over year on 7 of them.
Dividend
NKGN
"Dividend" not found for NKGN
MRK100/100
100/100
MRK's most recent dividend was $0.47 per share, based on a share price of $101.35. It was a payout ratio of 69.90% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
NKGen Biotech, Inc. Common Stock Summary
Nasdaq / NKGN
Healthcare
Biotechnology
Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.
Merck & Co., Inc. Summary
New York Stock Exchange / MRK
Healthcare
Drug Manufacturers - General
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare NKGN to other companies in the same or a similar industry.